AbbVie Inc. (0QCV.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:14PM GMT
| Previous close | 147.37 |
| Open | 150.11 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 146.93 - 147.40 |
| 52-week range | 146.93 - 147.40 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 2.191B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | 6.97 |
| Earnings date | 09 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
America’s top-selling drug Humira loses monopoly status
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss news that Abbvie’s Humira drug now faces competition.
- Business Wire
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
NORTH CHICAGO, Ill. & EXTON, Pa., January 06, 2023--AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
- Yahoo Finance Video
AbbVie’s Botox faces demand issues as prices soar
Health care reporter Anjalee Khemlani outlines how inflation and supply and demand issues are putting the squeeze on AbbVie's Botox treatments.
© 2023 Yahoo. All rights reserved.
